Loading
Houston surgeon who led the trial showing that giving cemiplimab before surgery can eliminate cutaneous squamous-cell carcinoma in about half of patients, sparing many from extensive operations.
Neil Gross is a head and neck surgical oncologist at MD Anderson Cancer Center. He was first author of the 2022 New England Journal of Medicine report of a phase 2 trial of neoadjuvant cemiplimab in resectable stage II to IV cutaneous squamous-cell carcinoma, in which about half of patients had a pathological complete response at surgery, and leads studies of neoadjuvant immunotherapy in head and neck cancers.
| Title | Journal | Year |
|---|---|---|
| Neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma | New England Journal of Medicine | 2022 |
Shares Advanced cutaneous squamous cell carcinoma, MD Anderson Cancer Center, Skin cancer (all types) and the tags skin, immunotherapy, trialist.
Shares Advanced cutaneous squamous cell carcinoma, Skin cancer (all types), Head and neck squamous cell carcinoma and the tags skin, immunotherapy, trialist.
Shares Advanced cutaneous squamous cell carcinoma, Skin cancer (all types) and the tags skin, immunotherapy, trialist.
Shares Skin cancer (all types) and the tags skin, immunotherapy, trialist.
Shares Advanced cutaneous squamous cell carcinoma, Skin cancer (all types) and the tags skin, immunotherapy.
Shares Head and neck squamous cell carcinoma and the tags surgery, immunotherapy, trialist.
Shares Skin cancer (all types) and the tags skin, trialist.
Shares Skin cancer (all types) and the tags skin, trialist.